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Abstract 
The relation of metabolic syndrome (MetS) with cardiovascular outcome may be less evident when preclinical 
cardiovascular disease is present. We explored, in a post hoc analysis, whether MetS predicts cardiovascular events in 
hypertensive patients with electrocardiographic left ventricular hypertrophy (ECG-LVH) in the Losartan Intervention For 
Endpoint (LIFE) reduction in hypertension study. MetS was defined by >or=2 risk factors plus hypertension: body mass 
index >or=30 kg/m(2), high-density lipoprotein (HDL)-cholesterol <1.0/1.3 mmol/l (<40/50 mg/dl) (men/women), glucose 
>or=6.1 mmol/l (>or=110 mg/dl) fasting or >or=7.8 mmol/l (>or=140 mg/dl) nonfasting or diabetes. Cardiovascular death 
and the primary composite end point (CEP) of cardiovascular death, stroke and myocardial infarction were examined. In 
MetS (1,591 (19.3%) of 8,243 eligible patients), low HDL-cholesterol (72%), obesity (77%) and impaired glucose (73%) 
were similarly prevalent, with higher blood pressure, serum creatinine and Cornell product, but lower Sokolow-Lyon 
voltage (all P<0.001). After adjusting for baseline covariates, hazard ratios for CEPs and cardiovascular death (4.8+/-1.1 
years follow-up) were 1.47 (95% confidence interval (CI), 1.27-1.71)- and 1.73 (95% CI, 1.38-2.17)-fold higher with MetS 
(both P<0.0001), and were only marginally reduced when further adjusted for diabetes, obesity, low HDL-cholesterol, 
non-HDL-cholesterol, pulse pressure and in-treatment systolic blood pressure and heart rate. Thus, MetS is associated 
with increased cardiovascular events in hypertensive patients with ECG-LVH, independently of single cardiovascular risk 
factors. 
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